 |
PDBsum entry 1si5
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hormone/growth factor
|
PDB id
|
|
|
|
1si5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hormone/growth factor
|
 |
|
Title:
|
 |
Protease-like domain from 2-chain hepatocyte growth factor
|
|
Structure:
|
 |
Hepatocyte growth factor. Chain: h. Fragment: protease-like domain. Synonym: scatter factor. Sf. Hepatopoeitin a. Lung fibroblast-derived mitogen. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108
|
|
Resolution:
|
 |
|
2.53Å
|
R-factor:
|
0.248
|
R-free:
|
0.301
|
|
|
Authors:
|
 |
D.Kirchhofer,X.Yao,M.Peek,C.Eigenbrot,M.T.Lipari,K.L.Billeci, H.R.Maun,P.Moran,L.Santell,R.A.Lazarus
|
Key ref:
|
 |
D.Kirchhofer
et al.
(2004).
Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
J Biol Chem,
279,
39915-39924.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
27-Feb-04
|
Release date:
|
28-Dec-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P14210
(HGF_HUMAN) -
Hepatocyte growth factor from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
728 a.a.
227 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
279:39915-39924
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
|
|
D.Kirchhofer,
X.Yao,
M.Peek,
C.Eigenbrot,
M.T.Lipari,
K.L.Billeci,
H.R.Maun,
P.Moran,
L.Santell,
C.Wiesmann,
R.A.Lazarus.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Hepatocyte growth factor (HGF), a plasminogen-related growth factor, is the
ligand for Met, a receptor tyrosine kinase implicated in development, tissue
regeneration, and invasive tumor growth. HGF acquires signaling activity only
upon proteolytic cleavage of single-chain HGF into its alpha/beta heterodimer,
similar to zymogen activation of structurally related serine proteases. Although
both chains are required for activation, only the alpha-chain binds Met with
high affinity. Recently, we reported that the protease-like HGF beta-chain binds
to Met with low affinity (Stamos, J., Lazarus, R. A., Yao, X., Kirchhofer, D.,
and Wiesmann, C. (2004) EMBO J. 23, 2325-2335). Here we demonstrate that the
zymogen-like form of HGF beta also binds Met, albeit with 14-fold lower affinity
than the protease-like form, suggesting optimal interactions result from
conformational changes upon cleavage of the single-chain form. Extensive
mutagenesis of the HGF beta region corresponding to the active site and
activation domain of serine proteases showed that 17 of the 38 purified
two-chain HGF mutants resulted in impaired cell migration or Met phosphorylation
but no loss in Met binding. However, reduced biological activities were well
correlated with reduced Met binding of corresponding mutants of HGF beta itself
in assays eliminating dominant alpha-chain binding contributions. Moreover, the
crystal structure of HGF beta determined at 2.53 A resolution provides a
structural context for the mutagenesis data. The functional Met binding site is
centered on the "active site region" including "triad"
and neighboring
"activation domain" residues Val(692), Pro(693), Gly(694), Arg(695),
and Gly(696) [c214-c219]. Together they define a region that bears remarkable
resemblance to substrate processing regions of serine proteases. Models of
HGF-dependent Met receptor activation are discussed.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 5.
FIG. 5. HGF x-ray structure and Met
binding site. A, structure and electron density of HGF "active
site region." The "active site catalytic triad residues" Asp578
[c102]-Gln534 [c57]-Tyr673 [c195] are depicted. Pro693 [c215]
adopts a different conformation than Trp [c215] found in serine
proteases and partially blocks the entrance to the "S1 pocket,"
which has a Gly667 [c189] at the bottom. B, stereo view of
active site regions of HGF (green) and plasmin
(gray). The pseudo-substrate inhibitor Glu-Gly-Arg-chloromethyl
ketone from the plasmin structure (yellow) fills the S1 pocket
and interacts with its Asp [c189] side chain. The main chain
amide nitrogen atoms that stabilize the oxyanion hole (blue
spheres) are structurally conserved in HGF . C, location of Met
binding site on HGF . Worm depiction of HGF
showing mutated residues
with <20% (red), 20-60% (orange), 60-80% (yellow), and >80%
(blue) of wild type HGF pro-migratory activity data in Fig. 2B.
The N terminus and three activation domain loops are in black.
Residue Lys649 [c173] would be colored yellow but is disordered
in the crystal structure and is not depicted. D,
solvent-accessible surface of HGF showing residues colored
as in C. The dotted line depicts the Met binding region from the
crystal structure of the complex of HGF with the Sema/PSI
domains of Met (22).
|
 |
Figure 6.
FIG. 6. HGF intermolecular contacts
and comparison to other proteins. A, intermolecular contacts in
HGF x-ray structure. The
reference molecule (green) has three crystal contacts. The blue
molecule arises from a 2-fold axis relating the N-terminal
regions Val496-Arg502 [c17-c23] and adjacent residues. The
N-terminal Val495 [c16] of the green and blue molecules are
depicted as spheres. The HGF -chain/ -chain
interface involving the N terminus and adjacent residues from
the [c140] and [c180] loops is shown by the arrow. The
salmon-colored molecule arises from a 2-fold axis relating
"active site regions." The side chains of Tyr673 [c195] are
shown. Residue C604S [c128] (sphere) in the yellow molecule
contacts the reference molecule in the [c70] loop. B, partial
sequences for HGF and homologous proteins at the border between
-
and -chains. HGF and
chymotrypsinogen numbering are above and below sequences,
respectively. The boxed Cys in the -chain forms a
disulfide bond with a Cys in the -chain. t-PA, tissue
plasminogen activator.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2004,
279,
39915-39924)
copyright 2004.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
E.Gherardi,
W.Birchmeier,
C.Birchmeier,
and
G.Vande Woude
(2012).
Targeting MET in cancer: rationale and progress.
|
| |
Nat Rev Cancer,
12,
89.
|
 |
|
|
|
|
 |
K.L.Eagleson,
D.B.Campbell,
B.L.Thompson,
M.Y.Bergman,
and
P.Levitt
(2011).
The autism risk genes MET and PLAUR differentially impact cortical development.
|
| |
Autism Res,
4,
68-83.
|
 |
|
|
|
|
 |
H.R.Maun,
D.Kirchhofer,
and
R.A.Lazarus
(2010).
Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer.
|
| |
Biol Chem,
391,
881-892.
|
 |
|
|
|
|
 |
K.A.Owen,
D.Qiu,
J.Alves,
A.M.Schumacher,
L.M.Kilpatrick,
J.Li,
J.L.Harris,
and
V.Ellis
(2010).
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
|
| |
Biochem J,
426,
219-228.
|
 |
|
|
|
|
 |
K.Miyazawa
(2010).
Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor.
|
| |
FEBS J,
277,
2208-2214.
|
 |
|
|
|
|
 |
L.Stevens,
L.McClelland,
A.Fricke,
M.Williamson,
I.Kuo,
and
G.Scott
(2010).
Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met.
|
| |
J Invest Dermatol,
130,
1636-1645.
|
 |
|
|
|
|
 |
R.Ganesan,
C.Eigenbrot,
and
D.Kirchhofer
(2010).
Structural and mechanistic insight into how antibodies inhibit serine proteases.
|
| |
Biochem J,
430,
179-189.
|
 |
|
|
|
|
 |
W.D.Tolbert,
J.Daugherty-Holtrop,
E.Gherardi,
G.Vande Woude,
and
H.E.Xu
(2010).
Structural basis for agonism and antagonism of hepatocyte growth factor.
|
| |
Proc Natl Acad Sci U S A,
107,
13264-13269.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
I.Bosanac,
H.R.Maun,
S.J.Scales,
X.Wen,
A.Lingel,
J.F.Bazan,
F.J.de Sauvage,
S.G.Hymowitz,
and
R.A.Lazarus
(2009).
The structure of SHH in complex with HHIP reveals a recognition role for the Shh pseudo active site in signaling.
|
| |
Nat Struct Mol Biol,
16,
691-697.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.G.Wright,
V.K.Singh,
J.J.Li,
J.H.Foley,
F.Miller,
Z.Jia,
and
B.E.Elliott
(2009).
Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human breast cancer progression model.
|
| |
Int J Cancer,
125,
1004-1015.
|
 |
|
|
|
|
 |
C.Basilico,
A.Arnesano,
M.Galluzzo,
P.M.Comoglio,
and
P.Michieli
(2008).
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.
|
| |
J Biol Chem,
283,
21267-21277.
|
 |
|
|
|
|
 |
P.M.Comoglio,
S.Giordano,
and
L.Trusolino
(2008).
Drug development of MET inhibitors: targeting oncogene addiction and expedience.
|
| |
Nat Rev Drug Discov,
7,
504-516.
|
 |
|
|
|
|
 |
D.Kirchhofer,
M.T.Lipari,
L.Santell,
K.L.Billeci,
H.R.Maun,
W.N.Sandoval,
P.Moran,
J.Ridgway,
C.Eigenbrot,
and
R.A.Lazarus
(2007).
Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
|
| |
Proc Natl Acad Sci U S A,
104,
5306-5311.
|
 |
|
|
|
|
 |
E.Gherardi,
S.Sandin,
M.V.Petoukhov,
J.Finch,
M.E.Youles,
L.G.Ofverstedt,
R.N.Miguel,
T.L.Blundell,
G.F.Vande Woude,
U.Skoglund,
and
D.I.Svergun
(2006).
Structural basis of hepatocyte growth factor/scatter factor and MET signalling.
|
| |
Proc Natl Acad Sci U S A,
103,
4046-4051.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
F.Carafoli,
D.Y.Chirgadze,
T.L.Blundell,
and
E.Gherardi
(2005).
Crystal structure of the beta-chain of human hepatocyte growth factor-like/macrophage stimulating protein.
|
| |
FEBS J,
272,
5799-5807.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Mazzone,
C.Basilico,
S.Cavassa,
S.Pennacchietti,
M.Risio,
L.Naldini,
P.M.Comoglio,
and
P.Michieli
(2004).
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice.
|
| |
J Clin Invest,
114,
1418-1432.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |